Literature DB >> 17461924

Treatment of acquired hemophilia A.

P W Collins1.   

Abstract

Acquired hemophilia A (AH) is an autoimmune disease that leads to potentially severe bleeding. Management relies on rapid and accurate diagnosis, control of bleeding episodes and eradication of the inhibitor by immunosuppression. There is extensive literature about the disease but only few controlled data are available. This paper reviews the current literature on treatment strategies for hemostatic therapy and inhibitor eradication. Potential future developments are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17461924     DOI: 10.1111/j.1538-7836.2007.02433.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  21 in total

1.  Autoimmune haemophilia.

Authors:  Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

2.  Successful response to rituximab in two cases of acquired haemophilia refractory to standard-therapy.

Authors:  P Machado; J M Raya; T Martín; L Morabito; M L Brito; J M Rodríguez-Martín
Journal:  Int J Hematol       Date:  2008-04-15       Impact factor: 2.490

Review 3.  The use of desmopressin in acquired haemophilia A: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2011-07-18       Impact factor: 3.443

4.  Consensus recommendations for the diagnosis and treatment of acquired hemophilia A.

Authors:  Peter Collins; Francesco Baudo; Angela Huth-Kühne; Jørgen Ingerslev; Craig M Kessler; Maria E Mingot Castellano; Midori Shima; Jean St-Louis; Hervé Lévesque
Journal:  BMC Res Notes       Date:  2010-06-07

5.  Acquired hemophilia A as a cause of acute upper gastrointestinal hemorrhage.

Authors:  Stephen McCain; Sadaf Gull; Jawad Ahmad; Declan Carey
Journal:  BMJ Case Rep       Date:  2014-02-05

Review 6.  Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

7.  Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry.

Authors:  A M Sevy; J F Healey; W Deng; P C Spiegel; S L Meeks; R Li
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

8.  Acquired Hemophilia A: Experience of a Tertiary Care Institute from North India.

Authors:  Narender Kumar; Sweta Rajpal; Jasmina Ahluwalia; Sunil Bose; Varun Uppal; Neelam Varma; Pankaj Malhotra; Subhash Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2017-09-18       Impact factor: 0.900

9.  Extracorporeal Treatment for the Acute und Long-Term Outcome of Patients with Life-Threatening Acquired Hemophilia.

Authors:  Heike Zeitler; Gudrun Ulrich-Merzenich; Darius Panek; Georg Goldmann; Natascha Vidovic; Hans-Hermann Brackmann; Johannes Oldenburg
Journal:  Transfus Med Hemother       Date:  2012-07-26       Impact factor: 3.747

Review 10.  Interventions for treating acute bleeding episodes in people with acquired hemophilia A.

Authors:  Yan Zeng; Ruiqing Zhou; Xin Duan; Dan Long; Songtao Yang
Journal:  Cochrane Database Syst Rev       Date:  2014-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.